146 related articles for article (PubMed ID: 26860847)
21. Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience.
Cerchione C; Catalano L; Pareto AE; Picardi M; Pane F
Support Care Cancer; 2015 Feb; 23(2):301-2. PubMed ID: 25341551
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies.
Gessner C; Potthoff K; Frost N
Oncol Res Treat; 2021; 44(3):93-102. PubMed ID: 33477145
[TBL] [Abstract][Full Text] [Related]
25. Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
Yokoyama M; Kusano Y; Inoue N; Nishimura N; Mishima Y; Nukada T; Hatake K; Terui Y
BMC Cancer; 2021 Apr; 21(1):358. PubMed ID: 33823836
[TBL] [Abstract][Full Text] [Related]
26. Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors.
Laali E; Fazli J; Sadighi S; Mohammadi M; Gholami K; Jahangard-Rafsanjani Z
J Oncol Pharm Pract; 2020 Mar; 26(2):428-433. PubMed ID: 31615347
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC; Szabo E; Gabriel S; Klastersky J; Tomey O; Mueller U; Schwartzberg L; Tang B
J Oncol Pharm Pract; 2018 Sep; 24(6):412-423. PubMed ID: 28614980
[TBL] [Abstract][Full Text] [Related]
28. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
Clemons M; Fergusson D; Simos D; Mates M; Robinson A; Califaretti N; Zibdawi L; Bahl M; Raphael J; Ibrahim MFK; Fernandes R; Pitre L; Aseyev O; Stober C; Vandermeer L; Saunders D; Hutton B; Mallick R; Pond GR; Awan A; Hilton J
Ann Oncol; 2020 Jul; 31(7):951-957. PubMed ID: 32325257
[TBL] [Abstract][Full Text] [Related]
29. The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study.
Li L; Ma S; Wu M; Tan X; Zhong S; Lang J
BMJ Support Palliat Care; 2019 Dec; 9(4):373-380. PubMed ID: 31467066
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).
Clemons M; Mazzarello S; Hilton J; Joy A; Price-Hiller J; Zhu X; Verma S; Kehoe A; Ibrahim MF; Sienkiewicz M; Stober C; Vandermeer L; Hutton B; Mallick R; Fergusson D
Support Care Cancer; 2019 Apr; 27(4):1345-1354. PubMed ID: 30099602
[TBL] [Abstract][Full Text] [Related]
31. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
32. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
Volovat C; Bondarenko I; Gladkov O; Buchner A; Lammerich A; Müller U; Bias P
Support Care Cancer; 2016 Dec; 24(12):4913-4920. PubMed ID: 27501966
[TBL] [Abstract][Full Text] [Related]
34. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
[TBL] [Abstract][Full Text] [Related]
35. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
[TBL] [Abstract][Full Text] [Related]
36. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
[TBL] [Abstract][Full Text] [Related]
37. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.
Fust K; Parthan A; Maschio M; Gu Q; Li X; Lyman GH; Tzivelekis S; Villa G; Weinstein MC
Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):39-52. PubMed ID: 28064553
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
